JY231

JY231 is an investigational chimeric antigen receptor T cell (CAR-T) therapy targeting CD19, developed for the treatment of B-cell malignancies and autoimmune diseases. Its mechanism involves engineering patient-derived T cells to express a CAR that recognizes and binds to the CD19 antigen on B cells, leading to targeted immunologic cytotoxicity and replacement of dysfunctional immune cells. The drug is being studied in early-phase clinical trials for conditions such as systemic lupus erythematosus, refractory B acute lymphoblastic leukemia, and various CD19-positive B-cell lymphomas. Developers include Guangdong Provincial People's Hospital and Shenzhen Genocury Biotech[1][2][7].